In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 371 to 380 of 423

TitleTypeExpected publication date
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Technology appraisal guidance
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]Technology appraisal guidanceTBC
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]Technology appraisal guidance
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease ID6432Technology appraisal guidanceTBC
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tirzepatide for managing overweight and obesity [ID6179]Technology appraisal guidance
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All